mTOR - Beyond transplantation

Current Opinion in Pharmacology

Volumn 5, Issue 4 SPEC. ISS., 2005, Pages 418-423

  Young, Deborah A ^a   Nickerson Nutter, Cheryl L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; IMMUNOPHILIN; INVAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; NEUROIMMUNOPHILIN; RAPAMYCIN; RAPAMYCIN DERIVATIVE; TAFA 93; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ALLERGIC ENCEPHALOMYELITIS; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; CELL ACTIVATION; CELL CYCLE G1 PHASE; CELL FUNCTION; CELL GROWTH; CELL TYPE; CLINICAL TRIAL; DENDRITIC CELL; DRUG SYNTHESIS; GRAFT REJECTION; GROWTH INHIBITION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; LUPUS VULGARIS; MULTIPLE SCLEROSIS; NONHUMAN; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; STROKE;

EID: 21644487580     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.03.004     Document Type: Review

References (57)

1. S.N. Sehgal Sirolimus: Its discovery, biological properties, and mechanism of action Transplant Proc 35 2003 7S-14S
2. T. Peng T.R. Golub D.M. Sabatini The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation Mol Cell Biol 22 2002 5575-5584
3. Y.G. Gangloff M. Mueller S.G. Dann P. Svoboda M. Sticker J.F. Spetz S.H. Um E.J. Brown S. Cereghini G. Thomas et al. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development Mol Cell Biol 24 2004 9508-9516
4. T.E. Harris J.C. Lawrence Jr. TOR signaling Sci STKE 2003 2003 re 15
5. N. Hay N. Sonenberg Upstream and downstream of mTOR Genes Dev 18 2004 1926-1945
6. J.M. Slavik D.G. Lim S.J. Burakoff D.A. Hafler Uncoupling p70(s6) kinase activation and proliferation: Rapamycin-resistant proliferation of human CD8(+) T lymphocytes J Immunol 166 2001 3201-3209
7. M.D. Vu F. Amanullah Y. Li G. Demirci M.H. Sayegh X.C. Li Different costimulatory and growth factor requirements for CD4+ and CD8+ T cell-mediated rejection J Immunol 173 2004 214-221
8. R.T. Peterson B.N. Desai J.S. Hardwick S.L. Schreiber Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein Proc Natl Acad Sci USA 96 1999 4438-4442
9. M. Hidalgo E.K. Rowinsky The rapamycin-sensitive signal transduction pathway as a target for cancer therapy Oncogene 19 2000 6680-6686
10. Jacinto E, Hall MN: Tor signalling in bugs, brain and brawn. [erratum appears in Nat Rev Mol Cell Biol 2003, 4:249] Nat Rev Mol Cell Biol 2003, 4:117-126.
11. J.B. Easton P.J. Houghton Therapeutic potential of target of rapamycin inhibitors Expert Opin Ther Targets 8 2004 551-564
12. R.A. Kirken Y.L. Wang Molecular actions of sirolimus: Sirolimus and mTor Transplant Proc 35 2003 227S-230S
13. A. Lorberg M.N. Hall TOR: The first 10 years Curr Top Microbiol Immunol 279 2004 1-18
14. L. Asnaghi P. Bruno M. Priulla A. Nicolin mTOR: A protein kinase switching between life and death Pharmacol Res 50 2004 545-549
15. C.G. Proud The multifaceted role of mTOR in cellular stress responses DNA Repair (Amst) 3 2004 927-934
16. D.H. Kim D. Sarbassov dos S.M. Ali R.R. Latek K.V. Guntur H. Erdjument-Bromage P. Tempst D.M. Sabatini GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR Mol Cell 11 2003 895-904
17. Y. Luo S.O. Marx H. Kiyokawa A. Koff J. Massague A.R. Marks Rapamycin resistance tied to defective regulation of p27Kip1 Mol Cell Biol 16 1996 6744-6751
18. R.J. White RNA polymerases I and III, growth control and cancer Nat Rev Mol Cell Biol 6 2005 69-78
19. P. Ghosh M.A. Buchholz S. Yano D. Taub D.L. Longo Effect of rapamycin on the cyclosporin A-resistant CD28-mediated costimulatory pathway Blood 99 2002 4517-4524
20. S. Dubois W. Shou L.S. Haneline S. Fleischer T.A. Waldmann J.R. Muller Distinct pathways involving the FK506-binding proteins 12 and 12.6 underlie IL-2-versus IL-15-mediated proliferation of T cells Proc Natl Acad Sci USA 100 2003 14169-14174
21. S.Y. Pai D.A. Fruman T. Leong D. Neuberg T.G. Rosano C. McGarigle J.H. Antin B.E. Bierer Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A Blood 84 1994 3974-3979
22. E.M. Breslin P.C. White A.M. Shore M. Clement P. Brennan mTOR: A protein kinase switching between life and death Br J Pharmacol 144 2005 791-800
23. K. Yokogami S. Wakisaka J. Avruch S.A. Reeves Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR Curr Biol 10 2000 47-50
24. H. Kusaba P. Ghosh R. Derin M. Buchholz C. Sasaki K. Madara D.L. Longo Interleukin-12-induced interferon-gamma production by human peripheral blood T cells is regulated by mammalian target of rapamycin (mTOR) J Biol Chem 280 2005 1037-1043
25. A.S. Kristof J. Marks-Konczalik E. Billings J. Moss Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-gamma is regulated by mammalian target of rapamycin J Biol Chem 278 2003 33637-33644
26. C.J. Fox P.S. Hammerman C.B. Thompson The Pim kinases control rapamycin-resistant T cell survival and activation J Exp Med 201 2005 259-266
27. C.J. Fox P.S. Hammerman R.M. Cinalli S.R. Master L.A. Chodosh C.B. Thompson The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor Genes Dev 17 2003 1841-1854
28. J.M. Slavik D.G. Lim S.J. Burakoff D.A. Hafler Rapamycin-resistant proliferation of CD8+ T cells correlates with p27kip1 down-regulation and bcl-xL induction, and is prevented by an inhibitor of phosphoinositide 3-kinase activity J Biol Chem 279 2004 910-919
29. H. Hackstein T. Taner A.F. Zahorchak A.E. Morelli A.J. Logar A. Gessner A.W. Thomson Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo Blood 101 2003 4457-4463
30. M. Abe A.W. Thomson Influence of immunosuppressive drugs on dendritic cells Transpl Immunol 11 2003 357-365
31. Y.R. Lee I.H. Yang Y.H. Lee S.A. Im S. Song H. Li K. Han K. Kim S.K. Eo Lee et al. Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells Blood 105 2005 3951-3955
32. H. Matsue C. Yang K. Matsue D. Edelbaum M. Mummert A. Takashima Contrasting impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A, and dexamethasone) on bidirectional dendritic cell-T cell interaction during antigen presentation J Immunol 169 2002 3555-3564
33. P.H. Chiang L. Wang C.A. Bonham X. Liang J.J. Fung L. Lu S. Qian Mechanistic insights into impaired dendritic cell function by rapamycin: inhibition of Jak2/Stat4 signaling pathway J Immunol 172 2004 1355-1363
34. P. Monti A. Mercalli B.E. Leone D.C. Valerio P. Allavena L. Piemonti Rapamycin impairs antigen uptake of human dendritic cells Transplantation 75 2003 137-145
35. A.M. Woltman S.W. van der Kooij P.J. Coffer R. Offringa M.R. Daha C. van Kooten Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression Blood 101 2003 1439-1445
36. L. Tian L. Lu Z. Yuan J.R. Lamb P.K. Tam Acceleration of apoptosis in CD4+CD8+ thymocytes by rapamycin accompanied by increased CD4+CD25+ T cells in the periphery Transplantation 77 2004 183-189
37. X.X. Zheng A. Sanchez-Fueyo M. Sho C. Domenig M.H. Sayegh T.B. Strom Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance Immunity 19 2003 503-514
38. S.N. Sehgal Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression Clin Biochem 31 1998 335-340
39. J. Camardo The Rapamune era of immunosuppression 2003: The journey from the laboratory to clinical transplantation Transplant Proc 35 2003 18S-24S
40. R. El-Sabrout V. Delaney M. Qadir F. Butt P. Hanson K.M. Butt Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients-a single center experience Transplant Proc 35 2003 89S-94S
41. B.D. Kahan Sirolimus-based immunosuppression: Present state of the art J Nephrol 17 Suppl 8 2004 S32-S39
42. S. Huang P.J. Houghton Targeting mTOR signaling for cancer therapy Curr Opin Pharmacol 3 2003 371-377
43. A. Panwalkar S. Verstovsek F.J. Giles Mammalian target of rapamycin inhibition as therapy for hematologic malignancies Cancer 100 2004 657-666
44. J.M. Peralba L. DeGraffenried W. Friedrichs L. Fulcher V. Grunwald G. Weiss M. Hidalgo Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients Clin Cancer Res 9 2003 2887-2892
45. E.K. Rowinsky Targeting the molecular target of rapamycin (mTOR) Curr Opin Oncol 16 2004 564-575
46. H. Burkhardt J.R. Kalden Xenobiotic immunosuppressive agents: therapeutic effects in animal models of autoimmune diseases Rheumatol Int 17 1997 85-90
47. L.M. Warner L.M. Adams S.N. Sehgal Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus Arthritis Rheum 37 1994 289-297
48. L.M. Warner T. Cummons L. Nolan S.N. Sehgal Sub-therapeutic doses of sirolimus and cyclosporin A in combination reduce SLE pathologies in the MRL mouse Inflamm Res 44 Suppl 2 1995 S205-S206
49. D.F. Mayer S.S. Kushwaha Transplant immunosuppressant agents and their role in autoimmune rheumatic diseases Curr Opin Rheumatol 15 2003 219-225
50. J. Pritchard S. Tsui N. Horst W.W. Cruikshank T.J. Smith Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves' disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor J Immunol 173 2004 3564-3569
51. D. Shegogue M. Trojanowska Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway J Biol Chem 279 2004 23166-23175
52. A. Heredia A. Amoroso C. Davis N. Le E. Reardon J.K. Dominique E. Klingebiel R.C. Gallo R.R. Redfield Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: An approach to suppress R5 strains of HIV-1 Proc Natl Acad Sci USA 100 2003 10411-10416
53. U. Nadiminti J.L. Arbiser Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis J Am Acad Dermatol 52 2005 17-19
54. K. Pong M.M. Zaleska Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases Curr Drug Targets CNS Neurol Disord 2 2003 349-356
55. L. Kappos J. Kuhle A. Gass L. Achtnichts E.W. Radue Alternatives to current disease-modifying treatment in MS: What do we need and what can we expect in the future? J Neurol 251 Suppl 5 2004 v57-v64
56. G.A.W. Bruyn G. Tate F. Caeiro J. Maldonado-Cocco R. Westhovens H. Tannenbaum M. Bell O. Forre O. Bjorneboe K.H. Abeywickrama et al. Everolimus in patients with rheumatoid arthritis receiving methotrexate: a 3-month, double-blind, randomized, placebo-controlled, parallel-group, proof-of-concept study Arth Rheum 50 2004 S378-S379
57. L.P. McMahon W. Yue R.J. Santen J.C. Lawrence Jr. Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex Mol Endocrinol 19 2005 175-183